Related Experiment Videos
Risperidone: clinical safety and efficacy in schizophrenia.
R L Borison1, A P Pathiraja, B I Diamond
1Department of Psychiatry, Medical College of Georgia, Augusta 30912-3800.
Psychopharmacology Bulletin
|January 1, 1992
Summary
Risperidone, a novel antipsychotic, demonstrated faster onset and better efficacy than haloperidol in treating schizophrenia. It also showed a superior side-effect profile, with fewer extrapyramidal symptoms and reduced tardive dyskinesia.
Area of Science:
- Psychopharmacology
- Neuroscience
- Clinical Psychiatry
Background:
- Schizophrenia is a complex psychiatric disorder often treated with antipsychotic medications.
- Traditional neuroleptics like haloperidol can have significant extrapyramidal side effects.
- Risperidone offers a unique pharmacological profile with combined serotonin and dopamine receptor antagonism.
Purpose of the Study:
- To compare the efficacy and safety of risperidone with haloperidol and placebo in patients with acute schizophrenic exacerbation.
- To evaluate the onset of antipsychotic activity and the incidence of extrapyramidal side effects.
Main Methods:
- A randomized, parallel-group, double-blind trial involving 36 schizophrenic patients.
- Comparison of risperidone, haloperidol, and placebo.
- Assessment of antipsychotic activity, extrapyramidal side effects, and adverse reactions.
Main Results:
- Risperidone exhibited a quicker onset of antipsychotic action compared to haloperidol.
- Risperidone was statistically superior to placebo and showed a trend toward superiority over haloperidol.
- Risperidone produced significantly fewer extrapyramidal side effects than haloperidol and did not differ from placebo.
- No major adverse reactions were observed with risperidone; tardive dyskinesia signs were reduced.
Conclusions:
- Risperidone may offer improved efficacy and a more favorable side-effect profile compared to standard neuroleptics like haloperidol.
- The unique pharmacology of risperidone contributes to its potential advantages in schizophrenia treatment.
- Further research is warranted to confirm these findings in larger patient populations.